Where it comes from
- Made in
- Islet cells, chromaffin cells and neuroendocrine tumours, cut from chromogranin A
- Sent out by
- With insulin and catecholamines
- Acts on
- Liver (glycogen breakdown)
- Fat cells (less glucose uptake)
- Beta cells (less insulin)
What it does
In medicine
- A research marker in neuroendocrine tumours: in one series of 92 patients it was raised in 64 percent, against 43 percent for chromogranin A itself 3
- No approved medicine copies it or blocks it, so the interest in it is as a measurement
Beyond the body’s own use
- PSTi8, a peptide that blocks pancreastatin, lowered insulin resistance and fat accumulation in obese and diabetic mice; it has not been given to a person 4
- Nothing containing pancreastatin is approved and it is not taken outside medicine. The open question is whether blocking it helps human type 2 diabetes as it helps the mouse 4
Sources
- Tatemoto et al., Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion, Nature 1986
- Allu et al., Functional Gly297Ser variant of pancreastatin as a cardiometabolic risk factor, Diabetes 2022
- Rustagi et al., Serum pancreastatin as a predictive neuroendocrine tumour marker, Journal of Surgical Oncology 2013
- Gupta et al., Pancreastatin inhibitor PSTi8 in hyperinsulinaemia-induced obesity, European Journal of Pharmacology 2019
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.